Adiponectin ameliorates iron-overload cardiomyopathy through the PPARα-PGC-1-dependent signaling pathway

Molecular Pharmacology

Volumn 84, Issue 2, 2013, Pages 275-285

  Lin, Heng ^c   Lian, Wei Shiung ^a,b   Chen, Hsi Hsien ^d   Lai, Pei Fang ^a,e   Cheng, Ching Feng ^a,b  

^a TZU CHI UNIVERSITY   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c Department of Physiology ^*  (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; HEME OXYGENASE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; IRON DEXTRAN; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; HEART FUNCTION; HEART LEFT VENTRICLE CONTRACTILITY; HEART MUSCLE CELL; IN VITRO STUDY; IN VIVO STUDY; IRON OVERLOAD; IRON THERAPY; KNOCKOUT MOUSE; MALE; MOUSE; MYOCARDITIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RAT; SIGNAL TRANSDUCTION; SUPPLEMENTATION; SURVIVAL; SURVIVAL RATE; WESTERN BLOTTING; WILD TYPE;

ADIPONECTIN; ANIMALS; CARDIOMYOPATHIES; CELL LINE; FEMALE; HEART FAILURE; HEME OXYGENASE-1; HUMANS; INFLAMMATION; IRON OVERLOAD; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCYTES, CARDIAC; PPAR GAMMA; RATS, WISTAR; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84880597267     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.083964     Document Type: Article

References (47)

1. Bradley PP, Priebat DA, Christensen RD, and Rothstein G (1982) Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78:206-209.
2. Bartfay WJ, Butany J, Lehotay DC, Sole MJ, Hou D, Bartfay E, and Liu PP (1999) A biochemical, histochemical, and electron microscopic study on the effects of ironloading on the hearts of mice. Cardiovasc Pathol 8:305-314.
3. Baldasseroni S, Mannucci E, Orso F, Di Serio C, Pratesi A, Bartoli N, Marella GA, Colombi C, Foschini A, and Valoti P et al. (2012) Adiponectin in outpatients with coronary artery disease: independent predictors and relationship with heart failure. Nutr Metab Cardiovasc Dis 22:292-299.
4. Barger PM, Brandt JM, Leone TC, Weinheimer CJ, and Kelly DP (2000) Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J Clin Invest 105:1723-1730.
5. Bulhak AA, Jung C, Ostenson CG, Lundberg JO, Sjöquist PO, and Pernow J (2009) PPAR-alpha activation protects the type 2 diabetic myocardium against ischemiareperfusion injury: involvement of the PI3-Kinase/Akt and NO pathway. Am J Physiol Heart Circ Physiol 296:H719-H727.
6. Beatty AL, Zhang MH, Ku IA, Na B, Schiller NB, and Whooley MA (2012) Adiponectin is associated with increased mortality and heart failure in patients with stable ischemic heart disease: data from the Heart and Soul Study. Atherosclerosis 220:587-592.
7. Cheng CF, Lian WS, Chen SH, Lai PF, Li HF, Lan YF, Cheng WT, and Lin H (2012) Protective effects of adiponectin against renal ischemia-reperfusion injury via prostacyclin-PPARa-heme oxygenase-1 signaling pathway. J Cell Physiol 227: 239-249.
8. Chen HH, Chen TW, and Lin H (2009) Prostacyclin-induced peroxisome proliferator-activated receptor-alpha translocation attenuates NF-kappaB and TNF-alpha activation after renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 297: F1109-F1118.
9. Crowe S and Bartfay WJ (2002) Amlodipine decreases iron uptake and oxygen free radical production in the heart of chronically iron overloaded mice. Biol Res Nurs 3:189-197.
10. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, and Lopaschuk GD et al. (2002) The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 109:121-130.
11. Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW, and Kelly DP (2003) A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci USA 100:1226-1231.
12. Forouhi NG, Harding AH, Allison M, Sandhu MS, Welch A, Luben R, Bingham S, Khaw KT, and Wareham NJ (2007) Elevated serum ferritin levels predict newonset type 2 diabetes: results from the EPIC-Norfolk prospective study. Diabetologia 50:949-956.
13. Fraga CG and Oteiza PI (2002) Iron toxicity and antioxidant nutrients. Toxicology 180:23-32.
14. Fujio Y, Nguyen T, Wencker D, Kitsis RN, and Walsh K (2000) Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 101:660-667.
15. Gabrielsen JS, Gao Y, Simcox JA, Huang J, Thorup D, Jones D, Cooksey RC, Gabrielsen D, Adams TD, and Hunt SC et al. (2012) Adipocyte iron regulates adiponectin and insulin sensitivity. J Clin Invest 122:3529-3540.
16. Genini D and Catapano CV (2006) Control of peroxisome proliferator-activated receptor fate by the ubiquitinproteasome system. J Recept Signal Transduct Res 26: 679-692.
17. Gilde AJ, van der Lee KA, Willemsen PH, Chinetti G, van der Leij FR, van der Vusse GJ, Staels B, and van Bilsen M (2003) Peroxisome proliferator- activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res 92:518-524.
18. Haemmerle G, Moustafa T, Woelkart G, Büttner S, Schmidt A, van de Weijer T, Hesselink M, Jaeger D, Kienesberger PC, and Zierler K et al. (2011) ATGLmediated fat catabolism regulates cardiac mitochondrial function via PPAR-a and PGC-1. Nat Med 17:1076-1085.
19. Hajer GR, van Haeften TW, and Visseren FL (2008) Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 29:2959-2971.
20. Hopkins TA, Ouchi N, Shibata R, and Walsh K (2007) Adiponectin actions in the cardiovascular system. Cardiovasc Res 74:11-18.
21. Huss JM, Kopp RP, and Kelly DP (2002) Peroxisome proliferator-activated receptor coactivator-1alpha (PGC-1alpha) coactivates the cardiac-enriched nuclear receptors estrogen-related receptor-alpha and-gamma. Identification of novel leucinerich interaction motif within PGC-1alpha. J Biol Chem 277:40265-40274.
22. Huss JM, Levy FH, and Kelly DP (2001) Hypoxia inhibits the peroxisome proliferator-activated receptor alpha/retinoid X receptor gene regulatory pathway in cardiac myocytes: a mechanism for O2-dependent modulation of mitochondrial fatty acid oxidation. J Biol Chem 276:27605-27612.
23. Huss JM, Torra IP, Staels B, Giguère V, and Kelly DP (2004) Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Mol Cell Biol 24:9079-9091.
24. Kahn E, Baarine M, Pelloux S, Riedinger JM, Frouin F, Tourneur Y, and Lizard G (2010) Iron nanoparticles increase 7-ketocholesterol-induced cell death, inflammation, and oxidation on murine cardiac HL1-NB cells. Int J Nanomedicine 5: 185-195.
25. Khan RS, Kato TS, Chokshi A, Chew M, Yu S, Wu C, Singh P, Cheema FH, Takayama H, and Harris C et al. (2012) Adipose tissue inflammation and adiponectin resistance in patients with advanced heart failure: correction after ventricular assist device implantation. Circ Heart Fail 5:340-348.
26. Konishi M, Haraguchi G, Ohigashi H, Ishihara T, Saito K, Nakano Y, and Isobe M (2011) Adiponectin protects against doxorubicin-induced cardiomyopathy by antiapoptotic effects through AMPK up-regulation. Cardiovasc Res 89:309-319.
27. Ku BJ, Kim SY, Lee TY, and Park KS (2009) Serum ferritin is inversely correlated with serum adiponectin level: population-based cross-sectional study. Dis Markers 27:303-310.
28. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, and Hiraoka H et al.; Osaka CAD Study Group. Coronary artery disease (2003) Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85-89.
29. Lehman JJ, Barger PM, Kovacs A, Saffitz JE, Medeiros DM, and Kelly DP (2000) Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest 106:847-856.
30. Lian WS, Lin H, Cheng WT, Kikuchi T, and Cheng CF (2011) Granulocyte-CSF induced inflammation-associated cardiac thrombosis in iron-loading mouse heart and can be attenuated by statin therapy. J Biomed Sci 18:26.
31. Lin H, Lin TN, Cheung WM, Nian GM, Tseng PH, Chen SF, Chen JJ, Shyue SK, Liou JY, and Wu CW et al. (2002) Cyclooxygenase-1 and bicistronic cyclooxygenase-1/prostacyclin synthase gene transfer protect against ischemic cerebral infarction. Circulation 105:1962-1969.
32. Lin H, Yu CH, Jen CY, Cheng CF, Chou Y, Chang CC, and Juan SH (2010) Adiponectin-mediated heme oxygenase-1 induction protects against iron-induced liver injury via a PPARa dependent mechanism. Am J Pathol 177:1697-1709.
33. Maury E and Brichard SM (2010) Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 314:1-16.
34. Mojiminiyi OA, Marouf R, and Abdella NA (2008) Body iron stores in relation to the metabolic syndrome, glycemic control and complications in female patients with type 2 diabetes. Nutr Metab Cardiovasc Dis 18:559-566.
35. Oudit GY, Sun H, Trivieri MG, Koch SE, Dawood F, Ackerley C, Yazdanpanah M, Wilson GJ, Schwartz A, and Liu PP et al. (2003) L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med 9:1187-1194.
36. Pischon T, Hu FB, Girman CJ, Rifai N, Manson JE, Rexrode KM, and Rimm EB (2011) Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women. Atherosclerosis 219:322-329.
37. Rowe GC, Jiang A, and Arany Z (2010) PGC-1 coactivators in cardiac development and disease. Circ Res 107:825-838.
38. Shibata R, Ouchi N, Ito M, Kihara S, Shiojima I, Pimentel DR, Kumada M, Sato K, Schiekofer S, and Ohashi K et al. (2004) Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 10:1384-1389.
39. Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, Funahashi T, Ouchi N, and Walsh K (2005) Adiponectin protects against myocardial ischemiareperfusion injury through AMPK-and COX-2-dependent mechanisms. Nat Med 11:1096-1103.
40. Springer J, Anker SD, and Doehner W (2010) Adiponectin resistance in heart failure and the emerging pattern of metabolic failure in chronic heart failure. Circ Heart Fail 3:181-182.
41. Tian L, Luo N, Zhu X, Chung BH, Garvey WT, and Fu Y (2012) Adiponectin-AdipoR1/2-APPL1 signaling axis suppresses human foam cell formation: differential ability of AdipoR1 and AdipoR2 to regulate inflammatory cytokine responses. Atherosclerosis 221:66-75.
42. Vaiopoulos AG, Marinou K, Christodoulides C, and Koutsilieris M (2012) The role of adiponectin in human vascular physiology. Int J Cardiol 155:188-193.
43. Wang Z, Zhu T, Qiao C, Zhou L, Wang B, Zhang J, Chen C, Li J, and Xiao X (2005) Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 23:321-328.
44. Wang Y, Lau WB, Gao E, Tao L, Yuan Y, Li R, Wang X, Koch WJ, and Ma XL (2010) Cardiomyocyte-derived adiponectin is biologically active in protecting against myocardial ischemia-reperfusion injury. Am J Physiol Endocrinol Metab 298: E663-E670.
45. Won H, Kang SM, Shin MJ, Oh J, Hong N, Park S, Lee SH, Jang Y, and Chung N (2012) Plasma adiponectin concentration and its association with metabolic syndrome in patients with heart failure. Yonsei Med J 53:91-98.
46. Zhu W, Cheng KK, Vanhoutte PM, Lam KS, and Xu A (2008) Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci (Lond) 114:361-374.
47. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, and Rapisarda F et al. (2002) Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13:134-141.